Improvement of cancellous bone microstructure in patients on. teriparatide following alendronate pretreatment

被引:19
|
作者
Fahrleitner-Pammer, Astrid [1 ]
Burr, David [2 ]
Dobnig, Harald [1 ]
Stepan, Jan J. [3 ,4 ]
Petto, Helmut [5 ]
Li, Jiliang [6 ]
Krege, John H. [7 ]
Pavo, Imre [5 ]
机构
[1] Med Univ Graz, Dept Internal Med, Div Endocrinol & Metab, Auenbruggerpl 15, A-8036 Graz, Austria
[2] Indiana Univ Sch Med, Dept Anat & Cell Biol, Indianapolis, IN USA
[3] Charles Univ Prague, Inst Rheumatol, Prague, Czech Republic
[4] Charles Univ Prague, Fac Med 1, Prague, Czech Republic
[5] Lilly Res Ctr, Vienna, Austria
[6] Indiana Univ Purdue Univ, Dept Biol, Indianapolis, IN USA
[7] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN USA
关键词
Teriparatide; PINP; Cancellous bone microstructure; Alendronate pretreatment; Tumover markers; PARATHYROID-HORMONE; 1-34; POSTMENOPAUSAL WOMEN; BIOCHEMICAL MARKERS; MINERAL DENSITY; SEVERE OSTEOPOROSIS; BMD RESPONSE; THERAPY; TURNOVER; STRENGTH; PINP;
D O I
10.1016/j.bone.2016.05.004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
An increase in procollagen type I amino-terminal propeptide (PINP) early after teriparatide initiation was shown to correlate with increased lumbar spine areal BMD and is a good predictor of the anabolic response to teriparatide. Few data exist correlating PINP and bone microstructure, and no data exist in patients on teriparatide following prior potent antiresorptive treatment. This exploratory analysis aimed to investigate the effects of teriparatide on cancellous bone microstructure and correlations of bone markers with microstructure in alendronate-pretreated patients. This was a post hoc analysis of changes in bone markers and three-dimensional indices of bone microstructure in paired iliac crest biopsies from a prospective teriparatide treatment study in postmenopausal women with osteoporosis who were either treatment-naive (TN, n = 16) or alendronate-pretreated (ALN, n = 29) at teriparatide initiation. Teriparatide (20 mu g/day) was given for 24 months; biopsies were taken at baseline and endpoint, and serum concentrations of PINP and type 1 collagen cross-linked C-telopeptide (beta CTX) were measured at intervals up to 24 months. In the TN and ALN groups, respectively, mean (SD) increases in three-dimensional bone volume/tissue volume were 105 (356)% (P = 0.039) and 55 (139)% (P < 0.005) and trabecular thickness 30.4 (30)% (P < 0.001) and 30.8 (53)% (P < 0.001). No significant changes were observed in trabecular number or separation. In the ALN patients, 3-month change of neither PINP nor beta CTX correlated with indices of cancellous bone microstructure. However, 12-month changes in biochemical bone markers correlated significantly with improvements in bone volume/tissue volume, r = 0.502 (P < 0.01) and r = 0.378 (P < 0.05), trabecular number, r = 0.559 (P < 0.01) and r = 0.515 (P < 0.01), and reduction of trabecular separation, r = -0.432 (P < 0.05) and r = -0.530 (P < 0.01), for PINP and SCDC, respectively. We conclude that cancellous bone microstructure improved with teriparatide therapy irrespective of prior antiresorptive use. (C) 2016 The Authors. Published by Elsevier Inc.
引用
收藏
页码:16 / 24
页数:9
相关论文
共 39 条
  • [21] NOCTURNAL STIMULATION OF PARATHYROID-HORMONE - A MECHANISM TO EXPLAIN THE CONTINUED IMPROVEMENT IN BONE-MINERAL DENSITY FOLLOWING ALENDRONATE THERAPY
    GREENSPAN, SL
    HOLLAND, S
    MAITLANDRAMSEY, L
    POKU, M
    FREEMAN, A
    ROSENBLATT, M
    GERTZ, B
    JOURNAL OF BONE AND MINERAL RESEARCH, 1995, 10 : S449 - S449
  • [22] Bone quality of the newest bone formed after two years of teriparatide therapy in patients who were previously treatment-naïve or on long-term alendronate therapy
    B. Hofstetter
    S. Gamsjaeger
    F. Varga
    H. Dobnig
    J. J. Stepan
    H. Petto
    I. Pavo
    K. Klaushofer
    E. P. Paschalis
    Osteoporosis International, 2014, 25 : 2709 - 2719
  • [23] Bone quality of the newest bone formed after two years of teriparatide therapy in patients who were previously treatment-na⟨ve or on long-term alendronate therapy
    Hofstetter, B.
    Gamsjaeger, S.
    Varga, F.
    Dobnig, H.
    Stepan, J. J.
    Petto, H.
    Pavo, I.
    Klaushofer, K.
    Paschalis, E. P.
    OSTEOPOROSIS INTERNATIONAL, 2014, 25 (12) : 2709 - 2719
  • [24] Effects of monthly intravenous ibandronate on bone mineral density and microstructure in patients with primary osteoporosis after teriparatide treatment: The MONUMENT study
    Chiba, Ko
    Yamada, Shuta
    Yoda, Itaru
    Era, Makoto
    Yokota, Kazuaki
    Okazaki, Narihiro
    Ota, Shingo
    Isobe, Yusaku
    Miyazaki, Satsuki
    Tashiro, Shigeki
    Nakashima, Sawako
    Morimoto, Shimpei
    Sato, Shuntaro
    Tsukazaki, Tomoo
    Watanabe, Tsuyoshi
    Enomoto, Hiroshi
    Yabe, Yoshihiro
    Yonekura, Akihiko
    Tomita, Masato
    Ito, Masako
    Osaki, Makoto
    BONE, 2021, 144
  • [25] Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial
    Takada, Junichi
    Dinavahi, Rajani
    Miyauchi, Akimitsu
    Hamaya, Etsuro
    Hirama, Toshiyasu
    Libanati, Cesar
    Nakamura, Yoichi
    Milmont, Cassandra E.
    Grauer, Andreas
    JOURNAL OF BONE AND MINERAL METABOLISM, 2020, 38 (03) : 310 - 315
  • [26] Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial
    Junichi Takada
    Rajani Dinavahi
    Akimitsu Miyauchi
    Etsuro Hamaya
    Toshiyasu Hirama
    Cesar Libanati
    Yoichi Nakamura
    Cassandra E. Milmont
    Andreas Grauer
    Journal of Bone and Mineral Metabolism, 2020, 38 : 310 - 315
  • [27] Bone turnover after alendronate dose reduction following prolonged standard full dose treatment in postmenopausal osteoporosis patients
    Segal, E.
    Shen-Orr, Z.
    Raz, B.
    Ish-Shalom, S.
    CALCIFIED TISSUE INTERNATIONAL, 2008, 82 : S247 - S248
  • [28] Monthly intravenous alendronate treatment can maintain bone strength in osteogenesis imperfecta patients following cyclical pamidronate treatment
    Harada, Daisuke
    Kashiwagi, Hiroko
    Ueyama, Kaoru
    Oriyama, Kyoko
    Hanioka, Yuki
    Sakamoto, Natsuko
    Kondo, Kawai
    Kishimoto, Kanako
    Izui, Masafumi
    Nagamatsu, Yuiko
    Yamada, Hiroyuki
    Tanaka, Hiroyuki
    Namba, Noriyuki
    Seino, Yoshiki
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2020, 33 (11): : 1391 - 1397
  • [29] Correction to: Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial
    Junichi Takada
    Rajani Dinavahi
    Akimitsu Miyauchi
    Etsuro Hamaya
    Toshiyasu Hirama
    Cesar Libanati
    Yoichi Nakamura
    Cassandra E. Milmont
    Andreas Grauer
    Journal of Bone and Mineral Metabolism, 2020, 38 : 605 - 605
  • [30] Changes in bone mineral density following discontinuation or continuation of alendronate therapy in glucocorticoid-treated patients - A retrospective, observational study
    Emkey, R
    Delmas, PD
    Goemaere, S
    Liberman, UA
    Poubelle, PE
    Daifotis, AG
    Verbruggen, N
    Lombardi, A
    Czachur, M
    ARTHRITIS AND RHEUMATISM, 2003, 48 (04): : 1102 - +